Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL-225 vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/m L.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP1A2 and to a lesser extent CYP2E1, CYP3A4; exhibits nonlinear pharmacokinetics at high concentrations.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 40% bound to albumin (primarily); binding is concentration-independent.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.3–0.7 L/kg; distributes freely into tissues and breast milk; Vd reflects moderate tissue penetration and rapid equilibration.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral: 100% (complete absorption); bioavailability not significantly affected by food. Rectal: ~80% (variable due to absorption site).
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No specific GFR-based adjustment required; monitor serum theophylline levels as renal impairment may affect clearance.
No data; not applicable.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 50-75%; Child-Pugh C: reduce dose by 75-90% or consider alternative. Frequent serum level monitoring is mandatory.
No data; not applicable.
Initial: 5 mg/kg orally every 6 hours; titrate based on serum levels. Usual maintenance: 10-20 mg/kg/day divided every 6 hours. Not recommended under 1 year without specialist advice.
No data; not applicable.
Start at lower dose (e.g., 112.5 mg every 6 hours) due to decreased clearance; titrate slowly with close serum level monitoring. Target lower end of therapeutic range (8-12 mcg/m L) if tolerated.
No data; not applicable.
No FDA black box warning.
None
Narrow therapeutic index; serum levels must be monitored (target 5-15 mcg/m L),Risk of seizure and cardiac arrhythmias at toxic levels,Increased seizure risk in patients with preexisting seizure disorders,Use with caution in liver impairment, congestive heart failure, and elderly,May cause tachycardia, palpitations, and exacerbation of arrhythmias
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or other xanthines (e.g., caffeine, theobromine),Pre-existing cardiac arrhythmias, particularly tachyarrhythmias,Active seizure disorder,Severe hepatic impairment
Hypersensitivity to arformoterol or any component of the formulation
Avoid excessive caffeine from coffee, tea, cola, and chocolate which can increase side effects. High-protein, low-carbohydrate diets may increase theophylline clearance. Charcoal-broiled foods and cruciferous vegetables (e.g., broccoli, cabbage) may induce metabolism and lower levels.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline crosses the placenta. First trimester: No clear association with major malformations in human studies, but limited data. Second/third trimester: Risk of fetal tachycardia, jitteriness, and irritability at high maternal serum levels (toxicity). May cause transient neonatal withdrawal symptoms (apnea, vomiting) if used near term.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk; M/P ratio approximately 0.7. Infant serum levels can reach therapeutic levels, especially with maternal doses >10 mg/kg/day. Use with caution; monitor infant for signs of irritability or insomnia. AAP considers compatible with breastfeeding but observe infant.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Clearance of theophylline decreases in pregnancy, especially in third trimester, leading to prolonged half-life. Dose reduction may be required to avoid toxicity; monitor serum levels closely. Typically, total daily dose may need reduction by 20-30% in late pregnancy. Postpartum, clearance normalizes quickly, necessitating dose increase.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Theophylline has a narrow therapeutic index; target serum concentration is 5-15 mcg/m L. Monitor levels due to variable clearance. CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., rifampin, smoking) significantly alter levels. Use with caution in hepatic impairment, heart failure, and elderly. Slow IV infusion over 20-30 minutes for loading dose to avoid hypotension and arrhythmias. Caffeine and theobromine (chocolate) can increase toxicity risk.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take the medication exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and limit caffeine intake (coffee, tea, cola, chocolate) as they can affect drug levels.,Report symptoms of toxicity immediately: nausea, vomiting, diarrhea, restlessness, insomnia, rapid heartbeat, or seizures.,Do not crush or chew sustained-release tablets; swallow whole.,Keep all appointments for blood tests to monitor theophylline levels.,Inform your doctor of all medications you are taking, especially antibiotics, seizure medicines, and heart medications.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL-225 vs AEROLONE, answered by our medical review team.
THEOPHYL-225 is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL-225 and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL-225 is: 225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/m L.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL-225 and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL-225 is classified as Category C. Theophylline crosses the placenta. First trimester: No clear association with major malformations in human studies, but limited data. Second/third trimester: Risk of fetal tachycar. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.